Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists uncover immune cell clues in rare scleroderma

NCT ID NCT04995588

Knowledge-focused Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 235 people to understand how certain immune cells, called innate T cells, might be involved in systemic sclerosis (a rare disease that causes hardening of the skin and organs). Researchers compared patients with systemic sclerosis to those with other autoimmune diseases and healthy volunteers. They measured different types of these immune cells and their activity in blood samples to find patterns that could explain the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

235 people

The number who actually took part.

Started

Feb 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * SSc according to the 2013 ACR/EULAR 2013 criteria (or the 2001 Leroy's criteria for early SSc) * Patients with others connective tissue disease: * Systemic erythematosus lupus (SLE) according to the 2019 ACR/EULAR criteria * Primary Sjögren syndrome (pSS) according to the 2016 ACR/EULAR criteria * Rheumatoid arthritis according to the 2010 ACR/EULAR criteria * Idiopathic inflammatory myopathy (IIM) according to the 2017 ACR/EULAR criteria * Healthy subjects from general population without known autoimmune disease or connective tissue disease * ≥18 years-old Exclusion Criteria: * Overlap syndrome (including secondary Sjögren syndrome) * Weight \<55 kgs * Known primary cell immunodeficiency * Past of autologous or allogenic hematopoietic stem cell transplantation * Solid neoplasia or malignant hemopathy in remission for less than 12 months an * Chemotherapy and/or immune checkpoint inhibitors in the last 12 months * Systemic retinoids * Active infection and/or antibiotics in the last 2 weeks * Known active chronic infection among HIV, HTLV, viral hepatitis, syphilis * Vaccination in the last 4 weeks * Subject refusing genetic analysis for the present study * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic inflammatory myopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic inflammatory myopathy rheumatoid arthritis Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic sclerosis

Contacts and locations

Locations

  • CHU poitiers

    Poitiers, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.